{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:53:45Z","timestamp":1761598425186,"version":"3.44.0"},"reference-count":32,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1136\/dtb.2022.240809rep","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:46:39Z","timestamp":1648561599000},"page":"92-95","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Republished: What obstetricians should be aware of \u2013 serious side effects of antibiotic toxoplasmosis treatment in pregnancy"],"prefix":"10.1136","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3524-2371","authenticated-orcid":false,"given":"Sara","family":"Ardabili","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Cantonal Hospital Lucerne, Luzern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Kohl","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Cantonal Hospital Lucerne, Luzern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fclseven","family":"G\u00fcl","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Cantonal Hospital Lucerne, Luzern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Hodel","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Cantonal Hospital Lucerne, Luzern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"2025082700541303000_60.6.92.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2005.10.006"},{"key":"2025082700541303000_60.6.92.2","doi-asserted-by":"publisher","DOI":"10.1097\/00006254-200105000-00025"},{"key":"2025082700541303000_60.6.92.3","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piu077"},{"key":"2025082700541303000_60.6.92.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(99)70224-3"},{"key":"2025082700541303000_60.6.92.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)08220-8"},{"key":"2025082700541303000_60.6.92.6","first-page":"1","article-title":"Toxoplasmosis during pregnancy and infancy. A new approach for Switzerland","volume":"138","author":"Boubaker","year":"2008","journal-title":"Swiss Med Wkly"},{"key":"2025082700541303000_60.6.92.7","unstructured":"Petersen E , Salmi LR , Kaminski M . National public health policies and routine programs to prevent congenital toxoplasmosis. Europe 2005."},{"key":"2025082700541303000_60.6.92.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60072-5"},{"key":"2025082700541303000_60.6.92.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.fawpar.2019.e00036","article-title":"Treatment of toxoplasmosis: current options and future perspectives","volume":"15","author":"Konstantinovic","year":"2019","journal-title":"Food Waterborne Parasitol"},{"key":"2025082700541303000_60.6.92.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197405162902003"},{"key":"2025082700541303000_60.6.92.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7197.1511"},{"key":"2025082700541303000_60.6.92.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-0328(02)02325-X"},{"key":"2025082700541303000_60.6.92.13","first-page":"193","article-title":"[Congenital toxoplasmosis treatment]","volume":"15","author":"Serranti","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025082700541303000_60.6.92.14","doi-asserted-by":"crossref","first-page":"386.e1","DOI":"10.1016\/j.ajog.2018.05.031","article-title":"Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial","volume":"219","author":"Mandelbrot","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"2025082700541303000_60.6.92.15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajog.2018.08.001","article-title":"Systematic screening and treatment of toxoplasmosis during pregnancy: is the glass half full or half empty?","volume":"219","author":"Montoya","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"2025082700541303000_60.6.92.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2005.07.019"},{"key":"2025082700541303000_60.6.92.17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis234"},{"key":"2025082700541303000_60.6.92.18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu724"},{"key":"2025082700541303000_60.6.92.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000351"},{"key":"2025082700541303000_60.6.92.20","doi-asserted-by":"publisher","DOI":"10.1080\/08035250500251999"},{"key":"2025082700541303000_60.6.92.21","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/30.6.1303"},{"key":"2025082700541303000_60.6.92.22","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/30.6.1309"},{"key":"2025082700541303000_60.6.92.23","unstructured":"Daveluy A , Haramburu F , Bricout H . Review of data related to side effects of drugs used in congenital toxoplasmosis. Bordeaux, France 2005."},{"key":"2025082700541303000_60.6.92.24","doi-asserted-by":"publisher","DOI":"10.1179\/2047773213Y.0000000094"},{"key":"2025082700541303000_60.6.92.25","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-017-0206-8"},{"key":"2025082700541303000_60.6.92.26","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199614030-00001"},{"key":"2025082700541303000_60.6.92.27","article-title":"Ascertainment of risk of serious adverse reactions associated with chemoprophylactic antimalarial drugs","volume":"68","author":"Phillips-Howard","year":"1990","journal-title":"Bull World Health Organ"},{"key":"2025082700541303000_60.6.92.28","doi-asserted-by":"publisher","DOI":"10.1136\/thx.44.4.307"},{"key":"2025082700541303000_60.6.92.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.297.6658.1240"},{"key":"2025082700541303000_60.6.92.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.290.6462.113"},{"key":"2025082700541303000_60.6.92.31","doi-asserted-by":"publisher","DOI":"10.1177\/014107689008300208"},{"key":"2025082700541303000_60.6.92.32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S1081-1206(10)62394-0","article-title":"Hypersensitivity syndrome associated with dapsone\/pyrimethamine (Maloprim) antimalaria chemoprophylaxis","volume":"88","author":"Thong","year":"2002","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2022.240809rep","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:54:27Z","timestamp":1756281267000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2022.240809rep"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,5,30]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/dtb.2022.240809rep"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2022.240809rep","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2022,3,29]]}}}